Cormorant Asset Management, LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001583977
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2023 · 49 positions · Total reported value $1.71B · Top-10 concentration 65.1% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 81.4% · 9 new · 37 cut · 2 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -24.1% · vs SPY -26.2% · Prev Value $1.95B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -13.0% · vs SPY -15.1% · Latest Value $1.40B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q3 2023 13F filing, Cormorant Asset Management, LP disclosed 49 equity positions with a combined reported value of $1.71B. The filing implies a focused portfolio: its ten largest positions account for 65.1% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2023 were MLTX ($464.10M), BBIO ($122.95M), AMAM ($114.12M). By sector, the heaviest allocations are Health Care 67.6%, Industrials 1.5%.
Versus the prior quarter, Cormorant Asset Management, LP opened 9 new positions, trimmed 37 and fully exited 2, a turnover rate of 81.4% of positions.
The largest new positions opened in Q3 2023 were MLTX ($464.10M), BBIO ($122.95M), AMAM ($114.12M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2023)
- MLTX MOONLAKE IMMUNOTHERAPEUTICS · $464.10M
- BBIO BRIDGEBIO PHARMA INC · $122.95M
- AMAM AMBRX BIOPHARMA INC · $114.12M
- ACLX ARCELLX INC · $77.14M
- APLS APELLIS PHARMACEUTICALS INC · $76.08M
- CBAY CYMABAY THERAPEUTICS INC · $57.40M
- OLMA OLEMA PHARMACEUTICALS INC · $55.63M
- GPCR STRUCTURE THERAPEUTICS INC · $53.26M
Fully Exited (vs previous quarter)
No tracked position was fully exited this quarter.
Insider Transactions (Form 4)
Latest Cormorant Asset Management, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-29 | Sell | Corbus Pharmaceuticals Holdings, Inc. | 425,000 | $4.10 | SEC filing |
| 2026-08-10 | Buy | BlossomHill Therapeutics, Inc. | 312,500 | $16.00 | SEC filing |
| 2026-08-10 | Conversion | BlossomHill Therapeutics, Inc. | 1,701,541 | — | SEC filing |
| 2026-08-10 | Conversion | BlossomHill Therapeutics, Inc. | 1,599,993 | — | SEC filing |
| 2026-04-28 | Sell | BRIGHT MINDS BIOSCIENCES INC. | 109,331 | $89.50 | SEC filing |
Fund Profile
Cormorant Asset Management, LP, based in Boston, MA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 57 positions worth $1.40B in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).
Firm Snapshot
- Headquarters: BOSTON, MA, United States
- SEC registration: 801-79513 (status: Approved), registered 2014-04-15
- Regulatory AUM (Form ADV): $3.84B as of 2026-05-27
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 7 private funds, of which 1 hedge funds
Portfolio Structure
- 57 positions · $1.40B reported value (Q3 2026)
- Top 10 holdings = 56.4% of reported value
- Largest position: PBLS (PARABILIS MEDICINES INC) at 10.7%
- Average position size: $24.53M
Sector Tilt
- Health Care 92.7%
- Industrials 1.3%
- Financials 1.1%
- (classified holdings cover 95% of value)
Quarterly Activity
- Q3 2026: 9 new, 1 added, 37 reduced, 2 exited
- 10 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
8.14M | $464.10M | 27.07% | New | |
| 2 |
|
4.66M | $122.95M | 7.17% | New | |
| 3 |
|
9.92M | $114.12M | 6.66% | New | |
| 4 |
|
2.15M | $77.14M | 4.50% | New | |
| 5 |
|
2.00M | $76.08M | 4.44% | New | |
| 6 |
|
3.85M | $57.40M | 3.35% | New | |
| 7 |
|
4.50M | $55.63M | 3.25% | New | |
| 8 |
|
1.06M | $53.26M | 3.11% | New | |
| 9 |
|
3.57M | $49.14M | 2.87% | New | |
| 10 |
|
1.23M | $47.03M | 2.74% | New | |
| 11 |
|
2.62M | $46.58M | 2.72% | New | |
| 12 |
|
2.88M | $43.82M | 2.56% | New | |
| 13 |
|
665.00K | $33.90M | 1.98% | New | |
| 14 |
|
1.10M | $32.77M | 1.91% | New | |
| 15 |
|
4.20M | $32.29M | 1.88% | New | |
| 16 |
|
1.36M | $28.41M | 1.66% | New | |
| 17 |
|
1.18M | $26.25M | 1.53% | New | |
| 18 |
|
3.20M | $25.57M | 1.49% | New | |
| 19 |
|
140.00K | $23.67M | 1.38% | New | |
| 20 |
|
1.90M | $21.75M | 1.27% | New | |
| 21 |
|
10.81M | $21.30M | 1.24% | New | |
| 22 |
|
1.56M | $21.19M | 1.24% | New | |
| 23 |
|
2.62M | $21.13M | 1.23% | New | |
| 24 |
|
850.00K | $19.49M | 1.14% | New | |
| 25 |
|
2.95M | $16.89M | 0.98% | New | |
| 26 |
|
1.22M | $16.62M | 0.97% | New | |
| 27 |
|
9.50M | $16.25M | 0.95% | New | |
| 28 |
|
600.00K | $16.19M | 0.94% | New | |
| 29 |
|
575.00K | $14.52M | 0.85% | New | |
| 30 |
|
700.00K | $14.04M | 0.82% | New | |
| 31 |
|
250.00K | $14.03M | 0.82% | New | |
| 32 |
|
2.35M | $13.08M | 0.76% | New | |
| 33 |
|
1.76M | $11.24M | 0.66% | New | |
| 34 |
|
225.00K | $10.57M | 0.62% | New | |
| 35 |
|
1.00M | $9.75M | 0.57% | New | |
| 36 |
|
450.00K | $9.22M | 0.54% | New | |
| 37 |
|
593.04K | $5.96M | 0.35% | New | |
| 38 |
|
325.00K | $5.40M | 0.32% | New | |
| 39 |
|
350.00K | $4.64M | 0.27% | New | |
| 40 |
|
1.09M | $4.29M | 0.25% | New | |
| 41 |
|
561.60K | $3.63M | 0.21% | New | |
| 42 |
|
616.79K | $3.32M | 0.19% | New | |
| 43 |
|
612.08K | $2.94M | 0.17% | New | |
| 44 |
|
81.96K | $2.13M | 0.12% | New | |
| 45 |
|
1.18M | $2.01M | 0.12% | New | |
| 46 |
|
92.29K | $1.30M | 0.08% | New | |
| 47 |
|
392.17K | $913.75K | 0.05% | New | |
| 48 |
|
54.06K | $217.86K | 0.01% | New | |
| 49 |
|
25.66K | $198.38K | 0.01% | New | |
FAQ
What did Cormorant Asset Management, LP buy in 2023-Q3?
In its 2023-Q3 13F filing, Cormorant Asset Management, LP reported 49 equity positions worth $1.71B in aggregate; its largest disclosed positions were MLTX ($464.10M), BBIO ($122.95M), AMAM ($114.12M).
How large is Cormorant Asset Management, LP's portfolio?
Cormorant Asset Management, LP reported $1.71B of long equity holdings across 49 positions as of 2023-Q3. Top-10 holdings account for 65.1% of reported value.
What is Cormorant Asset Management, LP's investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.